Literature DB >> 25446728

Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.

Lena Öhman1, Hans Törnblom1, Magnus Simrén1.   

Abstract

The aetiology and pathology of IBS, a functional bowel disorder thought to lack an organic cause, is largely unknown. However, studies suggest that various features, such as altered composition of the gut microbiota, together with increased intestinal permeability, a changed balance in the enteroendocrine system and a dysregulated immune system in the gut, most likely have an important role in IBS. Exactly how these entities act together and give rise to symptoms is still unknown, but an altered gut microbiota composition could lead to dysregulation of the intestinal barrier as well as the enteroendocrine and the immune systems, which (through interactions with the nervous system) might generate symptoms. This Review highlights the crosstalk between the gut microbiota, the enteroendocrine system, the immune system and the role of intestinal permeability in patients with IBS.

Entities:  

Mesh:

Year:  2014        PMID: 25446728     DOI: 10.1038/nrgastro.2014.200

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  213 in total

1.  RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study.

Authors:  Michael Camilleri; Paula Carlson; Andres Acosta; Irene Busciglio; Asha A Nair; Simon J Gibbons; Gianrico Farrugia; Eric W Klee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-24       Impact factor: 4.052

2.  Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome.

Authors:  Erja Malinen; Lotta Krogius-Kurikka; Anna Lyra; Janne Nikkilä; Anne Jääskeläinen; Teemu Rinttilä; Terttu Vilpponen-Salmela; Atte Johannes von Wright; Airi Palva
Journal:  World J Gastroenterol       Date:  2010-09-28       Impact factor: 5.742

Review 3.  Gut hormones: emerging role in immune activation and inflammation.

Authors:  W I Khan; J E Ghia
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

4.  Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.

Authors:  Cesare Cremon; Luciana Gargano; Antonio M Morselli-Labate; Donatella Santini; Rosanna F Cogliandro; Roberto De Giorgio; Vincenzo Stanghellini; Roberto Corinaldesi; Giovanni Barbara
Journal:  Am J Gastroenterol       Date:  2009-01-13       Impact factor: 10.864

5.  Mucosal serotonin signaling is altered in chronic constipation but not in opiate-induced constipation.

Authors:  Meagan M Costedio; Matthew D Coates; Elice M Brooks; Lisa M Glass; Eric K Ganguly; Hagen Blaszyk; Allison L Ciolino; Michael J Wood; Doris Strader; Neil H Hyman; Peter L Moses; Gary M Mawe
Journal:  Am J Gastroenterol       Date:  2009-12-15       Impact factor: 10.864

6.  Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.

Authors:  L-H Wang; X-C Fang; G-Z Pan
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 7.  The effects of inflammation, infection and antibiotics on the microbiota-gut-brain axis.

Authors:  Premysl Bercik; Stephen M Collins
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

8.  Linking long-term dietary patterns with gut microbial enterotypes.

Authors:  Gary D Wu; Jun Chen; Christian Hoffmann; Kyle Bittinger; Ying-Yu Chen; Sue A Keilbaugh; Meenakshi Bewtra; Dan Knights; William A Walters; Rob Knight; Rohini Sinha; Erin Gilroy; Kernika Gupta; Robert Baldassano; Lisa Nessel; Hongzhe Li; Frederic D Bushman; James D Lewis
Journal:  Science       Date:  2011-09-01       Impact factor: 47.728

9.  Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota.

Authors:  Samah O Noor; Karyn Ridgway; Louise Scovell; E Katherine Kemsley; Elizabeth K Lund; Crawford Jamieson; Ian T Johnson; Arjan Narbad
Journal:  BMC Gastroenterol       Date:  2010-11-12       Impact factor: 3.067

10.  Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.

Authors:  P Schoenfeld; M Pimentel; L Chang; A Lembo; W D Chey; J Yu; C Paterson; E Bortey; W P Forbes
Journal:  Aliment Pharmacol Ther       Date:  2014-04-03       Impact factor: 8.171

View more
  55 in total

1.  Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome.

Authors:  Olga Bednarska; Susanna A Walter; Maite Casado-Bedmar; Magnus Ström; Eloísa Salvo-Romero; Maria Vicario; Emeran A Mayer; Åsa V Keita
Journal:  Gastroenterology       Date:  2017-07-13       Impact factor: 22.682

Review 2.  New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.

Authors:  Emanuele Sinagra; Gaetano Cristian Morreale; Ghazaleh Mohammadian; Giorgio Fusco; Valentina Guarnotta; Giovanni Tomasello; Francesco Cappello; Francesca Rossi; Georgios Amvrosiadis; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

Review 3.  The brain's Geppetto-microbes as puppeteers of neural function and behaviour?

Authors:  Roman M Stilling; Timothy G Dinan; John F Cryan
Journal:  J Neurovirol       Date:  2015-06-06       Impact factor: 2.643

Review 4.  Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders-an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop.

Authors:  Ricky McCullough; Jeremiah McCullough
Journal:  Transl Gastroenterol Hepatol       Date:  2017-03-17

Review 5.  Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

Review 6.  Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions.

Authors:  Michael Camilleri; Ibironke Oduyebo; Houssam Halawi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-08       Impact factor: 4.052

7.  Relationship Between Microbiota of the Colonic Mucosa vs Feces and Symptoms, Colonic Transit, and Methane Production in Female Patients With Chronic Constipation.

Authors:  Gopanandan Parthasarathy; Jun Chen; Xianfeng Chen; Nicholas Chia; Helen M O'Connor; Patricia G Wolf; H Rex Gaskins; Adil E Bharucha
Journal:  Gastroenterology       Date:  2015-10-13       Impact factor: 22.682

Review 8.  The Bacterial Connection between the Oral Cavity and the Gut Diseases.

Authors:  S Kitamoto; H Nagao-Kitamoto; R Hein; T M Schmidt; N Kamada
Journal:  J Dent Res       Date:  2020-05-28       Impact factor: 6.116

9.  Assessing the colonic microbiome, hydrogenogenic and hydrogenotrophic genes, transit and breath methane in constipation.

Authors:  P G Wolf; G Parthasarathy; J Chen; H M O'Connor; N Chia; A E Bharucha; H R Gaskins
Journal:  Neurogastroenterol Motil       Date:  2017-03-13       Impact factor: 3.598

Review 10.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.